A similar number in two tables does not prove the tables describe the same patient or treatment setting.
Context, not an automatic dose engine. These selected source summaries explain how to interpret the drug protocols. They do not select a regimen or convert one institution's dialysis protocol to a different modality.
UCSF Infectious Diseases Management Program
UCSF dialysis reference - applicability of its dialysis columns
Method: Modality and flow dependent Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
The UCSF intermittent-HD recommendations assume high-flux treatment. The CRRT framework assumes CVVHD at 2 L/hour ultrafiltration with residual native GFR below 10 mL/min. These assumptions do not establish dosing for every CRRT prescription, peritoneal dialysis or prolonged intermittent modality. Individual drug entries can have further qualifications. Confirm the actual modality, flow, residual function, indication and dosing weight before applying a UCSF row.
Local summary SHA-256: 0a34b8f58b05e3e2f6650291cea14bbfa8178763eab806c1455c3fefbdfa63b4
NIH / NIDDK
NIDDK - selecting the kidney-function measure for drug dosing
Method: CrCl versus indexed/absolute eGFR; source-specific Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
NIDDK notes that FDA does not endorse one estimating equation for every medicine. Drug labels were developed with differing measures, including serum creatinine, measured clearance and estimated kidney function. Preserve the metric actually used by each product or protocol.
When a result is close to a dosing cutoff, consider the combined 2021 CKD-EPI creatinine-cystatin C estimate. Creatinine-only estimates can be inaccurate with unusual body size, muscle mass or diet; measured clearance or filtration-marker assessment may help for narrow-therapeutic-index drugs.
For body size substantially different from 1.73 m2, an indexed estimate can be converted: absolute eGFR (mL/min) = reported eGFR (mL/min/1.73 m2) x BSA / 1.73. This arithmetic does not convert eGFR into Cockcroft-Gault CrCl.
Local summary SHA-256: 48b84327648f3f9f4c2dd3272a0ada4b83b2d1cbfd8d82b872be36489a9fe1bd
University of Nebraska Medical Center
Nebraska - caution with changing kidney function and beta-lactam dosing
Method: Dynamic AKI and augmented renal clearance Source date: Published 2022-03-09 Retrieved: 2026-09-05
This university educational review emphasizes that AKI can resolve rapidly and creatinine-based estimates lag behind dynamic clearance. Early automatic reductions can risk antibiotic underexposure, whereas persistent impairment can lead to accumulation. It calls for prospective outcome evidence and reassessment rather than a universal delay in renal adjustment. It supplies context, not a new numeric drug protocol or permission to ignore toxicity.